|Bid||94.25 x 800|
|Ask||94.61 x 800|
|Day's Range||93.38 - 94.85|
|52 Week Range||57.00 - 95.45|
|Beta (3Y Monthly)||0.98|
|PE Ratio (TTM)||50.50|
|Earnings Date||Feb 12, 2020 - Feb 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||94.69|
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the J. P. Morgan 38th Annual Healthcare Conference on Monday, January 13, 2020 at 8:30 am (PST) in San Francisco.
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
For innovative drugmakers, product cycles are everything. That's why investors are so intrigued with fast-growing Incyte stock right now.
The Dow Jones Industrial Average enjoyed a bullish month, as did small-cap and key growth stocks. Will these six names jam in December?
The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
The S&P 500 Health Care index has underperformed the market in 2019, up 15.2% to the S&P 500’s 25.8%. Shares of Edwards Lifesciences, which sells heart valves and monitoring equipment, are up 60.8% so far this year. In August, the Food and Drug Administration approved two Edwards devices, SAPIEN 3 and SAPIEN 3 Ultra, for a broader set of patients, following the release of positive trial results earlier in the year.
Incyte today announced that the U.S. Food and Drug Administration has accepted for Priority Review its New Drug Application for pemigatinib, a selective fibroblast growth factor receptor inhibitor, as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.
Discover 12 stocks, including Kirkland Lake Gold, InMode, Incyte, and Inphi expecting earnings growth above 50% this year.
The Dow Jones Industrial Average has lagged in a bullish fourth quarter as this index ETF races 2% higher. Growth stocks show solid post-breakout gains.
Incyte announces that numerous abstracts, including data from its clinical development programs for ruxolitinib , itacitinib and ponatinib will be presented at the upcoming American Society of Hematology Annual Meeting 2019 in Orlando, Florida from December 7-10, 2019.
Trading pro Anne-Marie Baiynd shares why Dow Jones giants Boeing and Caterpillar could offer potential gains — and what buy points she's using.
Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
Incyte stock is the IBD Stock Of The Day amid a breakout and enthusiasm for the biotech company's diversifying pipeline and $2 billion war chest. Incyte makes Jakafi, a blockbuster drug.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
Incyte cleared an 89.40 buy point. Incyte has been running up since late September, especially after the cancer-focused biotech reported earnings doubled in late October.
IBD Stock of the Day, Incyte broke out above an 89.40 buy point. Medical sector has seen lots of action lately. Incyte has a strong backbone with its Jakafi cancer drug. It's expanding its pipeline and has the cash for an acquisition if need be. Profitable biotech.